BR112023019984A2 - Composição para prevenir ou tratar doenças neurodegenerativas compreendendo compostos que induzem a expressão do gene antienvelhecimento klotho - Google Patents
Composição para prevenir ou tratar doenças neurodegenerativas compreendendo compostos que induzem a expressão do gene antienvelhecimento klothoInfo
- Publication number
- BR112023019984A2 BR112023019984A2 BR112023019984A BR112023019984A BR112023019984A2 BR 112023019984 A2 BR112023019984 A2 BR 112023019984A2 BR 112023019984 A BR112023019984 A BR 112023019984A BR 112023019984 A BR112023019984 A BR 112023019984A BR 112023019984 A2 BR112023019984 A2 BR 112023019984A2
- Authority
- BR
- Brazil
- Prior art keywords
- klotho
- composition
- compounds
- preventing
- neurodegenerative diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 4
- 230000003712 anti-aging effect Effects 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 108050004036 Klotho Proteins 0.000 abstract 3
- 230000004770 neurodegeneration Effects 0.000 abstract 3
- 102000015834 Klotho Human genes 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210042958 | 2021-04-01 | ||
| KR1020210130307A KR102375097B1 (ko) | 2021-04-01 | 2021-09-30 | 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 |
| PCT/KR2022/004341 WO2022211420A1 (ko) | 2021-04-01 | 2022-03-28 | 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019984A2 true BR112023019984A2 (pt) | 2024-04-02 |
Family
ID=80936324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019984A BR112023019984A2 (pt) | 2021-04-01 | 2022-03-28 | Composição para prevenir ou tratar doenças neurodegenerativas compreendendo compostos que induzem a expressão do gene antienvelhecimento klotho |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240358683A1 (https=) |
| EP (1) | EP4316487A4 (https=) |
| JP (1) | JP7728031B2 (https=) |
| KR (1) | KR102375097B1 (https=) |
| CN (1) | CN117136055A (https=) |
| AU (1) | AU2022251900B2 (https=) |
| BR (1) | BR112023019984A2 (https=) |
| CA (1) | CA3213904A1 (https=) |
| WO (1) | WO2022211420A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102375097B1 (ko) * | 2021-04-01 | 2022-03-17 | 주식회사 클로소사이언스 | 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 |
| JP7728030B2 (ja) * | 2021-04-01 | 2025-08-22 | クロトー サイエンシーズ カンパニー リミテッド | 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物を含む慢性腎疾患の予防または治療用組成物 |
| EP4434534A1 (en) | 2023-03-22 | 2024-09-25 | ADvantage Therapeutics, Inc. | Klotho mrna |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4088770A (en) * | 1971-05-04 | 1978-05-09 | Eli Lilly And Company | Substituted 2-anilinobenzoxazoles used as immunosuppressive agents |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| US20070066577A1 (en) * | 2003-04-03 | 2007-03-22 | Hea Young Park Choo | Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same |
| JP2008506686A (ja) | 2004-07-16 | 2008-03-06 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | ベータ−アミロイドペプチドの形成を阻害することによるアルツハイマー病治療用化合物及び製造 |
| EP1910385B1 (en) * | 2005-08-04 | 2013-07-24 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
| WO2010039186A2 (en) * | 2008-09-23 | 2010-04-08 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| WO2010129954A1 (en) * | 2009-05-08 | 2010-11-11 | Apogee Biotechnology Corporation | Treatment of ischemia-reperfusion injury |
| KR101372721B1 (ko) * | 2010-06-18 | 2014-03-14 | 이화여자대학교 산학협력단 | Ｉｎｔｅｒｌｅｕｋｉｎ―６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| KR101446301B1 (ko) * | 2013-04-11 | 2014-10-06 | 서울대학교산학협력단 | Cxcr3/cxcl10 길항제 화합물, 이의 제조방법 및 이를 포함하는 골 전이의 예방 및 치료용 약학 조성물 |
| KR20160069736A (ko) * | 2014-12-09 | 2016-06-17 | (주)아모레퍼시픽 | 메틸화된 카테킨을 유효성분으로 함유하는 Klotho 유전자 활성화용 조성물 |
| US10647689B2 (en) | 2015-04-28 | 2020-05-12 | Sanford Burnham Prebys Medical Discovery Institute | Apelin receptor agonists and methods of use thereof |
| KR101770310B1 (ko) * | 2015-08-24 | 2017-08-24 | 이화여자대학교 산학협력단 | 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물 |
| KR102064611B1 (ko) * | 2017-10-13 | 2020-01-09 | 이화여자대학교 산학협력단 | 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| KR102522955B1 (ko) | 2018-09-26 | 2023-04-19 | 미쓰비시 덴키 빌딩 솔루션즈 가부시키가이샤 | 엘리베이터 시스템 및 휴대 단말 |
| JP7412546B2 (ja) | 2019-10-02 | 2024-01-12 | 克洛索科学公司 | 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物およびその用途 |
| KR102749973B1 (ko) | 2020-04-21 | 2025-01-06 | 엘지마그나 이파워트레인 주식회사 | 전기모터 및 이를 구비한 전기차량 |
| KR102375097B1 (ko) * | 2021-04-01 | 2022-03-17 | 주식회사 클로소사이언스 | 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 |
-
2021
- 2021-09-30 KR KR1020210130307A patent/KR102375097B1/ko active Active
-
2022
- 2022-03-28 CN CN202280026649.3A patent/CN117136055A/zh active Pending
- 2022-03-28 EP EP22781539.6A patent/EP4316487A4/en active Pending
- 2022-03-28 JP JP2023561185A patent/JP7728031B2/ja active Active
- 2022-03-28 WO PCT/KR2022/004341 patent/WO2022211420A1/ko not_active Ceased
- 2022-03-28 BR BR112023019984A patent/BR112023019984A2/pt unknown
- 2022-03-28 CA CA3213904A patent/CA3213904A1/en active Pending
- 2022-03-28 AU AU2022251900A patent/AU2022251900B2/en active Active
- 2022-03-28 US US18/553,414 patent/US20240358683A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4316487A1 (en) | 2024-02-07 |
| CA3213904A1 (en) | 2022-10-06 |
| CN117136055A (zh) | 2023-11-28 |
| JP7728031B2 (ja) | 2025-08-22 |
| AU2022251900B2 (en) | 2025-09-18 |
| US20240358683A1 (en) | 2024-10-31 |
| EP4316487A4 (en) | 2025-04-09 |
| JP2024512818A (ja) | 2024-03-19 |
| AU2022251900A9 (en) | 2023-11-09 |
| AU2022251900A1 (en) | 2023-10-26 |
| WO2022211420A1 (ko) | 2022-10-06 |
| KR102375097B1 (ko) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023019984A2 (pt) | Composição para prevenir ou tratar doenças neurodegenerativas compreendendo compostos que induzem a expressão do gene antienvelhecimento klotho | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| BR112021022778A2 (pt) | Compostos e métodos para o tratamento de covid-19 | |
| BR112021017430A2 (pt) | Inibidores da proteína tirosina fosfatase e métodos de uso dos mesmos | |
| MY209609A (en) | Immunomodulators, compositions and methods thereof | |
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| BR112022019532A2 (pt) | Conjugados de neodegrader | |
| BR112013021236A2 (pt) | composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença | |
| EP4219713A3 (en) | Products and compositions | |
| BR112017012327A2 (pt) | benzamidas substituídas por 1,3-tiazol-2-il. | |
| BR112017016663A2 (pt) | oligômero, conjugado, composição, kit, e, métodos para inibir ou reduzir a expressão de proteína tau em uma célula e para tratar ou prevenir um distúrbio neurológico | |
| BR112022018645A2 (pt) | Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide | |
| BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| BR112021025676A2 (pt) | Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella | |
| BR112018076485A8 (pt) | Carotenoides microbianos afetando a composição microbiana do intestino | |
| BR112023017367A2 (pt) | Composições e métodos para inibição de ceto-hexoquinase (khk) | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| BR112022005757A2 (pt) | Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma | |
| CO2024013744A2 (es) | Moduladores de nlrp3 | |
| BR112022010411A2 (pt) | Composições bacterianas projetadas e usos das mesmas | |
| PH12019502096A1 (en) | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| BR112017007066A2 (pt) | composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade | |
| BR112022014844A2 (pt) | Tratamento de doenças associadas ao panx1 |